Work

Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps4622

Authors: Nataliya Mar, Siamak Daneshmand, David Joseph Benjamin, Anishka D'souza, Michael A. Daneshvar, Arash Rezazadeh

Institutions: University of California, Irvine, USC Norris Comprehensive Cancer Center, Hoag Memorial Hospital Presbyterian, UC Irvine Health

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410817133

Cites:

Cited by:

Related to: 10